trending Market Intelligence /marketintelligence/en/news-insights/trending/6dGehkxaT70Gk4n-HIryRQ2 content esgSubNav
In This List

Emerald Health closes investment in Abattis Bioceuticals unit

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Emerald Health closes investment in Abattis Bioceuticals unit

Emerald Health Therapeutics Inc. completed its previously announced acquisition of a 53% interest in Northern Vine Canada Inc., a unit of Abattis Bioceuticals Corp.

Emerald Health invested C$2.5 million into Northern Vine for the ownership interest. The company will also appoint three of its four directors.

Abattis will continue to own the remaining 47% of Northern Vine.